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1. Introduction 
Erectile Dysfunction (ED) is the persistent inability to achieve and or maintain penile 
erection sufficient for satisfactory sexual Intercourse. 1 In 1995 it was estimated that 152 million 
men world-wide experienced ED and it was projected that by 2025, the prevalence worldwide would 
be 320 million.2 In the United states alone, 34 million men suffer from ED3 while in China, 
according to Yang et al, 4 prevalence is reported to be 73.1% in the general population. 
Shaeer et al 5 in their study of the prevalence of ED in diverse nationalities representing a 
wide range of cultural, religious, racial and socio-economic backgrounds concluded that 
prevalence rates from various countries are difficult to compare because of variable 
definition and age range. So far, the most comprehensive epidemiological study of ED has 
been the Massachusetts male aging study6 which reported ED to be present in 10% of men 
aged between forty and fifty years and almost 70% in Men aged 70% years and above. 
 
 COUNTRIES PREVALENCE 
1. Malaysia 17.0% 
2. Germany 19.0% 
3. Japan 34.0% 
4. 
United States  
of America 
52.0% 
5. Morocco 53.6% 
6. Nigeria 57.4% 
7. Egypt 63.6% 
8. Turkey 64.3% 
9. China  73.1% 
10. Pakistan 80.8% 
Table 1. Reported Prevalence of ED in selected Countries. 
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In the early 1980s, issues of quality of life ( Qol) were brought into the fore of medical 
practice prompting the rise of ED into prominence as a diagnostic entity. According to 
Pomerville 7 ’20 years ago, ED did not exist as a diagnostic term. Its former name 
‘Impotence’ carried a heavy connotation – an impotent man was powerless, worthless, less 
than a man. Impotence was seldom discussed in the locker rooms or bed rooms of nations” 
Impotence was relegated and considered to be due to the wears and tears of the aging 
process for which there is no treatment. This is strongly supported by the following 
statement by Wyne et al:8 ”for centuries, sexual medicine was a taboo subject practiced by 
quasiscientists, back alley charlatans and village shamans. Because of a paucity of basic 
knowledge about the anatomy, Physiology and Pharmacology of the erectile process, many 
myths on causation and therapy were promulgated through time.” 
This perception has changed remarkably due to research into ED in the last century which 
led to the discovery that certain factors are associated with ED with a cause- effect 
relationship.9 10 Currently, there is a better understanding of the incidence, prevalence, 
etiology and risk factors for ED. 
ED is classified as psychogenic, neurological and vasculogenic. Vasculogenic erectile 
dysfunction, similar to coronary artery disease, is usually due to atherosclerosis, in the case 
of ED, arthrosclerosis of the branches of the pudendal artery. Cardiovascular risk factors are 
so classified because of their propensity for causing artherosclersis12 which may involve the 
coronary artery thereby predisposing the heart to myocardial hypoperfussion disease. The 
common denominator in ED and CAD therefore, is arthrosclerosis whose main causes are 
these life style abnormities referred to as cardiovascular risk factors. The implication of this 
is that the risk factors for ED and CAD are similar or are in fact the same.13 14 15 
Hypertension, Diabetes mellitus, dyslipidemia and cigarette smoking have been well 
documented as predisposing to atherosclerosis of the coronary artery which has earned 
them the term ‘cardiovascular risk factors”. Currently, reduced androgen level, particularly 
testosterone, is under intense research as another risk factor because of the vascular changes 
associated with it.16 Several epidemiological studies have demonstrated that ED is more 
prevalent in men with atherosclerotic disease than the general population. 17 It is now 
generally accepted that ED, like CAD, results from the endothelial dysfunction which 
usually co-exist with or predates true atherosclerotic vascular changes.18 
 
Documented Risk Factors CVS RISK FACTOR BEING 
EVALUATED 
Cigarette smoking 
Dyslipidemia 
Diabetes Mellitus 
Hypertension 
Low testosterone level 
 
Table 2. CVS risk factors. 
In spite of the adverse effects of ED on quality of life of the affected men, the disease is 
generally under-reported and under-treated19 due to poor self reporting as a result of 
cultural taboos, fear of stigmatization, ignorance on the part of the patient or physician and 
unavailability of specialists in the area. Erectile dysfunction is a treatable disease and many 
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men have been treated and have returned to normal life especially with the advent of the 
phosphodiesterase 5 inhibitors. 20 This chapter focuses on erectile dysfunction and its 
cardiovascular system correlates. 
2. Neuroanatomy and physiology of penile erection 
The human penis is made up of two dorsally located corpora cavernosa and one ventrally 
placed corpus spongiosum.21 The corpus spongiosum expands proximally to form the bulb 
of the penis while distally it expands to form the glans penis, the most sensitive part of the 
organ. Proximally, the two corpora cavernrnosa diverge laterally and are attached, one on 
each side, to the inferior surface of the ischio pubic rami.22 The erectile tissue proper is 
located in the corpora cavernosa and surrounded by a tough fibrous tissue called the tunica 
albuginea.  
The corpora cavernosa consist of sinusoids with smooth muscle lined internally by 
endothelium similar to that of blood vessels. The helicine arteries, the terminal branches of 
the cavernosal arteries, open directly into the sinusoids. The blood is drained by veins which 
course beneath the tunica albuginea before piercing it. These join the dorsal vein complex.  
The penis is innervated by both autonomic and somatic nerves; the latter supplies the skin 
while the former sub serves the erectile tissue proper.23 Somatic supply consist of free nerve 
endings (receptors) in the skin of the penis, usually up to ten times as numerous in the penile 
skin and the glans particularly. These receptors coalescence to form the dorsal nerve of the 
penis, a branch of the pudendal nerve which originates from the dorsal rami of S2 -4. 24 The 
nerve fibres are mainly unmyelinated C and A delta fibres which sub serve the sensation of 
pain, pressure and touch (tactile stimulus), the stimulus responsible for reflexogenic 
erection.The para sympathetic pathway which serves the cavernosa arises from neurons in the 
S2- 425 and follow the ventral rami. This group of cells constitutes the Onuf nucleus and their 
preganglionic fibres join the sympathetic fibers from the hypogastric plexus to form the pelvic 
plexus (pelvic splachnic nerves). The post ganglonic fibres (nervi erigentis ) arise from the 
pelvic plexus and passing anterior to the rectum and posteriolateral to the prostate, they pierce 
the pelvic membrane to reach the corpora cavernosa. They are often damaged during surgical 
procedures which involve total removal of the prostate and the rectum because of which these 
procedures are often complicated by erectile dysfunction.26  
The sympathetic pathway whose fibres are mainly inhibitory originate from T11 - L2 spinal 
segment. The fibres pass through the white rami to the sympathetic ganglion. Some of these 
fibres reach the inferior mesenteric and superior hypogastric plexus through the lumbar 
splanchnic nerves. From the hypogastric plexus, some fibres reach the pelvis and join the 
parasympathetic fibres to form the pelvic plexus. The fibres from the pelvic plexus which 
reach the carvenosa along with those from S2-4 are mainly from T10 -12. 27 These fibres also 
carry impulses which control ejaculation and may be damaged during radical retro 
peritoneal dissection as they course behind the peritoneum. 28 
The central control of penile erection depends on the input from somatic and autonomic 
pathways and environmental factors, which include smell, sight and thought of Sex. Tactile 
impulses from the dorsal nerve of the penis travel via the spino thalamic and spino reticular 
pathways to the thalamus and sensory cortex for sensory interpretation. Studies have shown 
that the medial pre-optic area and the para ventricular nucleus of the hypothalamus are the 
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integration centre for erection and sexual activity.29 It is currently suggested that there may 
be projections from the hypothalamic nuclei to the sacral erection centre, S2 – 4, as is found 
in animals. Other centres which contribute to control of sexual activity also abound in the 
mid brain and medulla.30 
Several neuro transmitters are involved in penile erection and control of sexual activity. The 
neuro transmitter traditionally associated with the parasympathetic (parasympathetic 
finally control erection) is acetylcholine while nor– adrenaline and adrenaline are involved 
in sympathetic transmission. Other neuro-transmitters secreted at the level of the autonomic 
nervous system in the genito-urinary tract are vaso- active intestinal peptide (VIP) and 
several prostaglandins. These neurotransmitters do not however, completely account for the 
events that lead to penile erection. Currently, the substance which is considered to act as the 
neurotransmitter involved in penile erection is a non adrenergic, non cholinergic (NANC) 
and it is now known to be nitric oxide (NO). 31 
Nitric oxide is a ubiquitous neuro-transmitter in the lower urinary tract 32 and its role in 
penile erection process is presently well documented. It is formed from L-arginine under the 
control of Nitric oxide synthase. 33 There are three isoforms of Nitric oxide synthase; eNos, 
nNos and iNos depending on the cell in which it is synthesized. Neural stimulation causes 
release of Nitric oxide from neurons while its release from endothelium is in response to 
sheer stress. 34 The neurotransmitters involved in the central control of penile erection and 
sexual activity include oxytocin, gama amminobutyric acid and serotonin.  
In the flaccid state, the smooth muscle of the cavernosa is semi contracted under the tonic 
influence of the sympathetic system, its intrinsic myogenic activity and endothelium derived 
factors such as prostaglandin F2 alpha. 37 In this state, the blood flow to the penis is kept at the 
barest minimum required to meet its nutritional needs at a pCo2 of 35mmHg.38 Following 
sexual stimulation, the non adrenergic non cholinergic fibres which accompany the 
parasympathetic to the cavernosa, release nitric oxide which triggers the erectile process 39. 
 
 Central (smell, thought) and tactile (penile skin) stimulus 
 Processing of resulting impulses by the Onuf nucleus. 
 Activation of the effector pathway (nervi-erigentes). 
 Release of neuronal NO following neuronal NO Synthase activation. 
 Activation of the NO-cGMP pathway. 
 Increase blood flow into the cavernous sinus-penile erection. 
 Increase flow stimulates release of endothelial NO- sustained erection 
Table 3. Summary of physiology of penile erection. 
Nitric oxide is a potent vasodilator which readily diffuses into the cell to initiate a series of 
bio-chemical events. Nitric oxide modulates the activities of guanylate cyclase, 40 an action 
which leads to the conversion of guanosine triphosphate (GTP) to cyclic guanosine 
monophosphate (cGMP). The latter, acting as a second messenger, regulates calcium 
channel activities including those of intracellular contractile proteins that lead to the 
relaxation of corpus cavernosal smooth muscle.41 Specifically, cGMP activates protein 
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Kinase G leading to a decrease in calcium influx into the cell which in turn causes activation 
of myokinase and finally, relaxation of corpora smooth muscle, a sine qua non in the erectile 
process 42. 
Penile erection is classified as: Central, reflexogenic and Nocturnal. 43 In central erection, the 
stimulus is from thought, site and smell related to Sexual intercourse which activates the 
spinal centres, the impulses of which travel through the parasympathetic to the corpora. 
Reflexogenic erection results from tactile stimulation of the dorsal nerve of the penis. The 
afferent pathway reaches the onuf nucleus which then activates the erectile parasympathetic 
pathway via the same process as in central erection. Nocturnal Penile tumescence (NPT) is 
currently poorly understood. It occurs during rapid eye movement sleep and it is presently 
thought to play a key role in keeping the erectile tissue per fussed. 3 
Following central or reflexogenic stimulus, there is activation of the parasympathetic erectile 
pathway with the release of nitric oxide and the consequent cascade of events which lead to 
relaxation of cavernous smooth muscle and the helicine arteries. The ensuing rapid influx of 
blood into the sinusoids leads to increased intra cavernosal pressure and compression of the 
sub tunical venous system against the tunica abulginea. There is reduced outflow in the 
presence of markedly increased inflow and the penis becomes firm and increased in size – 
phase of full erection. Through the pudendal nerve, sexual impulses also reach the ischio 
carveranosus and bulbospongiosus muscles which contract vigorously, further impeding 
venous drainage - phase of rigid erection. 
Penile detumescense is a consequence of the intense, diffuse sympathetic discharge which 
herald orgasm, emission and ejaculation. The catecholamines released in the process cause 
smooth muscle contraction, thereby terminating erection. The smooth muscle contraction 
leads to reduced blood flow into the sinusoids, reduced intra cavernosa pressure and the 
opening of the venous channels. There is therefore increased venous outflow in the presence 
of reduced arterial inflow. The trapped blood in the sinusoids is expelled and the penis 
becomes flaccid23.  
 
Fig. 1. Penile tumescence and detumescence 
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3. Atherosclerosis 
Arteries vary in wall thickness and size and based on these, they are classified as45 (A) 
Elastic or large arteries. A typical example is the aorta, Innorminate, subclavian and illiac 
arteries (b) Medium sized arteries typical of which are coronary arteries (c) Small arteries. 
These are usually less than 2mm in diameter, coursing for most of their path through the 
substance of the issue or organ. A good example is the pudendal and cavernosa arteries 
which supply the penile erectile tissue and upon which erection depends. The arterial wall, 
independent of class, is made up of three layers namely;  
1. Adventitia. This is a fibrous tissue which covers the artery externally and separates it 
from the surrounding structures or tissues. 
2. The media. This is responsible for most of the wall thickness and consists mostly of 
smooth muscle cells (SMC) which are under the tonic control of the endothelium.46 It is 
from this layer that SMC are recruited in the formation of atheroma. 
3. The intima. This consists of a single layer of endothelium which rests on a basement 
membraine. The endothelial cells are joined together by tight junctions which are 
normally impermeable to most substances in the blood. 
The endothelium is physiologically endowed to control the vessel in order to vary blood 
flow according to tissue, organ and regional requirements. It is in most part, responsible for 
the smooth flow of blood and therefore has profound effect on vascular reactivity and 
thrombogenesis. It inhibits platelet aggregation, reduces the recruitment of inflammatory 
cells into the intima and the entry of lipids into the arterial wall.  
The endothelium secretes a wide variety of substances with paracrine effect while also 
expressing receptors for various substances in the blood stream, the latter including 
hormones, local mediators and vasoactive substances. Based on these, the endothelium is 
capable of sensing and responding to local changes either by causing vasodilatation or 
constriction. The overall effect of endothelial reactivity is however vasodilatation or a 
tendency to vasodilatation reaching up to 80% in the penile arterial bed as against 15% in 
other tissues.47 48 
Nitric oxide (NO) is a major neurotransmitter produced by the endothelium and is responsible 
for the endothelium derived vasodilatation. It is produced, as a neurotransmitter, in most parts 
of the lower urinary tract either normally or pathologically.49 It inhibits cytochrome C oxidase, 
reduces oxygen consumption by the vasculature and inhibits or modifies the endothelial cells 
for circulating white blood cells. Its release is stimulated by acetyl choline, brandykin, 
substance P and sheer stress on the arterial wall. 
  Endothelial dysfunction is defined as a state of altered phenotype which leads to 
impairment of vascular reactivity or an induced surface which is thrombogenic or 
abnormally adhesive for inflammatory cells.45 This change may predate or co-exist with 
atherosclerosis and is characterized by loss of vascular reactivity. The initial phase is 
characterized by decreased bioavailability of nitric oxide either due to reduced 
production or increased breakdown. There is therefore loss of the endothelium derived 
smooth muscle relaxation with a tendency to vasoconstriction and increased peripheral 
resistance. These effects have been implicated in hypertension, diabetes mellitus, 
cigarette smoking and hyperlipidemia, all of which are risk factors for ED and CAD. 
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Endothelial dysfunction is a systemic disease and it is usually as a result of diverse 
injury including sheer stress, trauma and inflammation. It occurs in the initial and 
subsequent phases of atherosclerosis. Though all arterial beds are affected, the effects 
manifests earlier in the smaller vessel beds50 such as the pudendal artery which supply 
the erectile tissue of the penis. In the presence of endothelial dysfunction, the 
endothelium becomes unduly permeable, allowing substances such as lipids, proteins 
and macrophages into the intima, a sin-qua non for atherosclerotic changes. 
  Atherosclerosis is characterized by intimal lesion called atheroma or atheromatous 
plagues or fibrofatty plagues which project into the lumen of the vessel. It forms the 
common pathway through which the well documented cardiovascular risk factors 
cause their deleterious effects on the heart, cerebrum and the erectile tissues. 
Endothelial dysfunction results from inhibition of dimethyl arginine dimethyl amino 
hydrolase which catalyses the hydrolysis of asymmetric dimethyl arginine, an inhibitor 
of endothelial nitric oxide synthase. The subsequent uncoupling of eNos leads to 
endothelial oxidative stress and formation of peroxy nitrates, oxidation of pro-
inflammatory nuclear factor Kappa B and hence cellular inflammation.51 
Endothelial inflammation causes increase permeability of the endothelial cells and the tight 
junctions. The subsequent increased movement of lipids, protein and inflammatory cells, 
particularly macrophages into the intima, initiates the process of atherosclerosis which 
affects all the arterial bed. Timing of clinical appearance however depends on the severity 
and size of the affected vessel as up to 75% of the vessel lumen maybe occluded before 
effects become obvious.52 Smaller vessels such as the pudendal artery may be occluded up 
to ten years before bigger vessels like the coronary arteries are affected. This explains why 
erectile dysfunction usually precedes the occurrence of coronary artery diseases or stroke.  
 
Fig. 2. Mechnisms by which CVS risk factors cause ED and CAD 
4. Cardiovascular risk factors and erectile dysfunction  
4.1 Diabetes mellitus  
Diabetes mellitus(DM) is defined as persistent hyperglycemia secondary to relative or 
absolute insulin deficiency. This has a profound effect on protein, lipid and carbohydrate 
metabolism with a myriad of complications of which ED is one. These complications can 
broadly be classified as vascular or neurologic and ED has been documented in both classes. 
In DM, neurologic damage which may predispose to ED usually result from peripheral 
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neuropathy and ED is well known to be associated with both somatic and autonomic 
neuropathies. 53 Both types of autonomic neuropathies ie, axonal and demyelinating, occur 
in DM and are responsible for the ‘failure to initiate’ type of ED. 
Vascular damage from DM causes the ‘failure to fill’ type of erectile dysfunction. This 
results from endothelial dysfunction and or atherosclerosis both of which are companions of 
diabetes mellitus. Diabetes mellitus is associated with low grade inflammation, 
dyslipidemia, hypertension and the metabolic syndrome all of which, as independent 
entities, are risk factors for ED. This low grade inflammatory state in DM has been well 
documented by many authors who have demonstrated elevated c-Reactive protein, Tumor 
Necrosis Factor alpha (TNF) and interleukin 6 (IL-6) in diabetic patients with ED who have 
no other risk factors. 54 55 56 
The low grade inflammation in DM causes endothelial dysfunction which leads to an 
endothelium that is more thrombogenic and permeable to lipids, inflammatory cells such as 
macrophages. This initiates the process of atherosclerosis which is usually diffuse and 
occurs earlier in diabetic patients. (The reader is referred to standard vascular texts for the 
pathology of atherosclerosis) The ensuing diffuse atherosclerosis and micro-angiopathy is 
responsible for the nephropathy, retinopathy, stroke, coronary artery disease and ED that 
accompany DM. According to Meng et al, 57 higher glucose levels induces apoptosis in 
endothelial cells while Di Filippo et al 58 conclude that DM is associated with increased 
cardiovasular disease due to established risk factors such as dyslipdemia , hypertension and 
atherosclerosis as a result of increased inflammation. This leads to the production of free 
oxygen radicals, impaired NO metabolism and increased movement of lipids into the intima 
leading to early and diffuse atherosclerosis. Through this atherosclerotic damage, cerebral, 
cardiac, renal and erectile function maybe impaired.  
The pathophysiologic relationship between diabetes mellitus and erectile dysfunction, 
according to Moore et al, 59 is multifactorial. They proposed the mechanism of ED in DM to 
include elevated advance glycation end products, increased level of free oxygen radicals, 
impaired NO synthesis, increased endothelin B binding sites and ultrastructural changes, up 
regulated Rhoa/ Rho-Kinase pathway, NO dependent selective nitregic nerve degeneration 
and impaired c-GMP dependent kinase. Overall, there is impaired flow mediated dilatation 
in DM patients which is in part secondary to increased inflammation and endothelial and 
platelet activation60  
 
 Other associated CVS risk factors e.g. hypertension, dyslipidemia. 
 Low grade inflammation causing endothelial dysfunction. 
 Production of free O2 radicals, impaired NO metabolism. 
 Elevated advance glycation end products. 
 Increased endothelin B receptor binding sites. 
 Up regulation of RhOA/Rho-Kinase Pathway. 
 Nitric oxide dependent selective nitregic nerve degeneration.  
Table 4. Summary of Causes of ED in DM. 
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ED is highly common in type 2 DM (T2DM) patients and the duration of DM is usually 
longer in ED patients. The atherosclerotic process is usually ongoing, dynamic and 
progressive 61making the clinical course of ED in DM gradual and ED may be the only 
sign62. As DM, especially type 2, maybe present for years before diagnosis, many patients 
already have complications before or at presentation and this may include ED. Based on 
these, it has been proposed that ED should be regarded as an observable marker of DM. In a 
study of ED In diabetics, Sun et al 63 concluded that men with ED are more than twice likely 
to have DM, strongly so for men 45 years and below but not for men older than 66 years. 
Twelve percent of men studied by Deutsch et al 64 were found to have unrecognized DM 
while the Massachusetts Male Aging Study (MMAS) 65 showed that the probability of ED is 
three times more common in men who reported being treated for DM and figures as high as 
three quarters of all diabetics have been documented. DM has other complications such as 
leg ulcers which impact negatively on psyche and quality of life and in such patients, ED 
may be partly psychogenic. This should not be underestimated in the course of evaluation. 
4.2 Hypertension 
Essential hypertension is the leading risk factor for mortality worldwide accounting for 13% 
of all deaths globally.66 It is the most common non communicable disease in Nigeria67 and 
according to Essien et al,68 the mean venous blood glucose level of hypertensive adult 
Nigerians is higher than their normotensive counterparts. According to recent studies, 
approximately 67-68% of men with hypertension have some degree of erectile dysfunction.69 
Erectile dysfunction in hypertension, similar to diabetes mellitus, results from endothelial 
dysfunction and or atherosclerosis. Endothelial dysfunction in hypertension is caused by the 
sheer stress of elevated blood pressure on the vessel wall.70 This endothelial damage causes 
the impairment of endothelium derived relaxation. The inflammation which accompanies 
endothelial dysfunction leads to altered NO metabolism, formation of free oxygen radicals 
and an increased movement of lipids into the intima, a necessity for atheromatous vascular 
damage. Hypertension is associated with structural and functional changes in the arterial 
wall and this is responsible for the mortality and morbidity associated with it.71 
In a number of cardiovascular pathologies, such as hypertension and heart failure, 
according to Boulauger et al,72 the balance in the endothelial production of vasodialating 
mediators is altered. The underlying dysfunction is likely to be the consequence of the high 
blood pressure and could facilitate the maintenance of elevated peripheral resistance with 
subsequent development of atherosclerosis. The ensuing arterial stiffness is an independent 
cardiovascular risk factor.73 From this perspective, it can be deduced that hypertension is an 
independent risk factor for coronary heart disease and vasculogenic erectile dysfunction. In 
the work of Modebe74 in Nigeria, 8% of the untreated hypertension population had erectile 
dysfunction while this was 61% in the treated group. Treatment, rather than the 
hypertension therefore, may be responsible for the ED and may account for the non 
compliance with treatment frequently seen in this group of patients who may want to 
maintain their potency. This agrees with the of opinion of Shiri et al75 who in their study 
concluded that the risk of ED is higher in men suffering from treated hypertension and heart 
disease than in those with the untreated condition  
Erectile function and neuromuscular transmission are calcium dependent phenomena, 
which to a large extent, depends on the general physical well being of the man. Erectile 
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dysfunction is associated with the use of calcium channel blockers, angiotensin II antagonist, 
non selective alpha blockers and diuretics. The continuous use of diuretics, particularly 
thiazide diuretics, is often accompanied by dehydration, electrolyte imbalance and elevated 
blood sugar all of which may lead to ED or aggravate an already existing mild disease. ED is 
however not currently known to be associated with the use of organic nitrates, angiotensin 
converting enzymes (ACE) inhibitors, selective alpha blockers and drugs that lower serum 
lipid levels.  
 
 Ultrastructural changes in the vessel wall. 
 Endothelial dysfunction and atherosclerosis. 
 Medication side effect e.g. diuretics. 
 Target organ damage e.g. stroke and heart failure. 
Table 5. Summary of causes of ED in hypertension 
The preliminary report of the telmisartan alone, and in combination with ramipril global 
end point trial/telmisartan randomized assessment study in ACE – intolerant subjects with 
cardiovascular disease (ONTARGET/TRACEND) study76 has shown that on the contrary, 
calcium channel blockers tend to have a significant adverse effect on erectile function 
whereas diuretics, beta blockers, ACE inhibitors, ATI antagonist and alpha blockers do not. 
Treatment with ACE inhibitors and ATI antagonist or a combination of both is suggested to 
improve erectile function in cardiovascular high risk patients. 
On the overall, hypertension is complicated by numerous vascular conditions which impact 
negatively on the quality of life of the affected men. Apart from coronary heart disease and 
erectile dysfunction, conditions such as hypertensive renal damage, intermittent 
claudication, retinal damage and heart failure often complicate hypertension and lower the 
quality of life of these men, with severe effect on their psyche. Like DM therefore, the 
contribution of psychogenic erectile dysfunction in hypertensives should not be 
underestimated in the course of treatment. 
5. Cigarrette smoking/dylipidemia 
Cigarette smoking is currently a major health concern and in spite of the vigorous campaign 
against it, more people continue to take to smoking in many countries of the world. The 
most well mentioned and documented toxin of cigarette smoke is nicotine but others exist. 
Cigarette smoke is directly toxic to vascular endothelium77 and this culminates in vascular 
endothelial dysfunction, functional and architectural changes in the vessel wall.78 The 
cascade of events which follow this endothelial dysfunction is similar to that in DM and 
hypertension. The end result is atherosclerosis and its deleterious effect on penile erectile, 
cardiac and cerebral function.  
According to Chen et al, 79 an increased ED prevalence has been reported in patients with 
chronic obstructive airway diseases and sustained inflammation seem to play a central role 
in this linkage. Cigarette smoking has traditionally been associated to chronic obstructive 
airway disease (chronic bronchitis, emphysema) and through this mechanism, it may 
contribute significantly to the burden of ED. These conditions, similar to DM, are 
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accompanied by low level chronic inflammation, elevated c-Reactive protein and may be 
followed by diffuse endothelial dysfunction and atherosclerosis.80 This low grade 
inflammatory state allow increase in low density lipoprotein transport across the 
endothelium into the intima, thereby initiating the process of atherosclerosis. 
 Direct toxicity to vascular endothelium. 
 Functional and structural changes in vessel wall. 
 Chronic obstructive airway disease. 
 Endothelial dysfunction and atherosclerosis. 
 Reduction in concentration of NO synthase. 
Table 6. Summary of causes of ED in cigarette smoking and Dyslipidemia 
Dyslipidemia and obesity are major components of the metabolic syndrome (MS) which is 
currently well documented as being accompanied by a low systemic inflammatory state 
which predisposes to vascular endothelial dysfunction.81This is the underlying mechanism 
of ED in men who have the metabolic syndrome and concomitant ED. This is evidenced by 
the presence of raised level of inflammatory markers in the affected men. MS and obesity 
are linked to lowered serum testosterone82 in a double edge manner and low serum 
testosterone as an independent cardiovascular risk factor, is presently being examined. It is 
considered to be due to the reduced level of sex hormone binding globulin. Additionally, in 
obesity which is often present in MS, there is increased level of low density lipoprotein as a 
result of abnormal insulin metabolism.82 
A third of citizens of the United States are presently considered, by current definition, to be 
obese83 and the prevalence of MS in ED population is 45% compared with 24% in matched 
control.84 Conversely, the prevalence of ED in MS population is 34 – 43% and this depends 
on the number of independent risk factors-85 dyslipidemia, hypertension and diabetes 
mellitus. Dyshpidemia is also often an accompaniment of DM and hypertension in different 
combinations. However, dyslipidemia is an independent risk factor for ED and CAD.86 
Hypercholesterolemia has a well established link with endothelial dysfunction with 
oxidized low density lipoprotein being a key mediator.87 According to Brunner et al, 77 in 
familial hypercholesterolemia, endothelial dysfunction is present prior to clinical arterial 
disease. Endothelial dysfunction is related to particle size and concentration, 88 transport 
across the endothelium being inversely related to the particle size and directly to the 
concentration. This explains why low density lipoprotein, and not high density lipoproteins, 
89 is incriminated in endothelial dysfunction. Low density lipoprotein leads to reduction in 
endogenous NO synthase90 which in turn causes a reduced bioavailability of the 
endothelium derived relaxation factor, NO, probably by enhancing super oxide anion. 
Lipoproteins are transported across the endothelium by the process of transcytosis and in 
the presence of endothelial dysfunction, reduced NO bioavailability and increased 
concentration of LDL, this process is enhanced leading to atherosclerotic vascular changes. 
In contrast, HDLs are presently considered to enhance endothelial function and a low 
concentration may predispose to endothelial dysfunction.91 
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6. Coronary Artery Disease (CAD) 
In Britain, approximately a quarter of all deaths among men and one-fifth of all deaths 
among women are due to ischemic heart diseases.92 In England and Wales, 30% of all deaths 
among men and 22% among women are as a result of ischemic heart diseases. 93 Through 
atherosclerotic narrowing, cardiac ischemia precipitates cardiac malfunction and sometimes 
infarction of the myocardium. The major risk factors for endothelial dysfunction and 
atherosclerosis, which are also the cause of CAD and ED, are hypertension DM, 
dyslipidemia and cigarette smoking and these life style abnormalities have been 
traditionally documented as cardiovascular risk factors.  
ED is related to CAD in a double edged manner. ED represents an independent risk factor 
for feature CVS event independent of classic risk factors such as hypertension, DM and 
dyslipidema 94. The common denominator for ED, CAD and these cardiovascular risk 
factors is endothelial dysfunction which is usually diffuse, affecting several arterial beds 
such as the pudendal and coronary arteries and thereafter culminating in atherosclerosis. In 
2003 Montorsi et al 95 proposed the small artery theory to explain the earlier occurrence of 
ED than CAD. Coronary arteries, being larger than the pudendal arteries, take a longer 
period for occlusion from endothelial dysfunction and atherosclerotic vacscular narrowing 
to occur. Eventually, as the atherosclerosis progresses, larger vessels such as the cerebral, 
coronary and renal arteries become involved and this precipitates target organ damage. 
Several studies have documented this with clear evidence. In the study by Pritzter, 96 of 20 
men, out of a study group of 50 who were investigated angiographically following self 
reported ED without any other complaints, all have demonstrable disease. They compared 
sexual function to the penile stress test as a window to the hearts of men. Vlachopoulos et al 
97 investigated men whose only complaint was ED and found angiographically silent CAD 
in 19%. Bensal et al 98 also in their work documented 56% asymptomatic CAD in an ED 
population. Ultimately, in some of these men, CAD become overt, and as documented by 
Rodriguez et al 99 in DM, taking an average period of 38.8 months. According to their study, 
100% of DM men experienced ED prior to onset of CAD. Based on this premise, ED is 
currently considered a sentinel event for CAD as both have their origin from endothelial 
dysfunction and atherosclerosis.100 These are mounting evidence therefore, that ED is an 
early predictor of CAD and that there is need for physicians to evaluate men who present 
with ED, with no other cardiovascular symptom, for CAD and its risk factors. 101 
CAD is an independent risk factor for ED and the prevalence of ED in CAD population is 
remarkable. James et al102 studied the relation between ED and CAD in men referred for 
stress myocardial perfusion single-photon emission computed tomography (MPS). They 
concluded that men sent for MPS have a higher prevalence of ED. Also, men with ED 
exhibited a higher prevalence of severe CAD and left ventricular dysfunction than those 
without ED. In the work of Bensal, 98 75% of men with CAD have symptoms of ED and 91% 
of their ED populations have cardiovascular risks. This has implication for men who have 
CAD and who intend to engage in sexual activity. Herschorn100 in his work on 
cardiovascular safety of phosphodiestares 5 inhibitors said that “in general, sexual activity 
has an effect similar to mild-moderate exercise in increasing heart rate, blood pressure, 
cardiac output and respiratory rate. The degree of change in these physiologic parameters 
however, is greater than expected because of disproportionate increase in sympathetic 
www.intechopen.com
 
Erectile Dysfunction Complicating Cardiovascular Risk Factors and Disease 
 
111 
activation. The absolute risk of sexual activity triggering a myocardial infarction (MI) is low. 
Men with CAD or previous MI have a 10-fold higher risk, which means that during sexual 
inter-course, the probability of such a man having MI is 20/Million/hour”. 
7. Heart failture (HF) 
Several cardiovascular disorders cause heart failure which may be left or right sided failure. 
These include hypertension, congenital and acquired heart defects and cardiomyophathies. 
Left side failure usually results from hypertension, mitral and aortic valvular abnormalities 
which may be acquired or congenital. Eventually, left sided failure leads to pulmonary 
hypertension and with continued back pressure, right sided failure which is referred to as 
congestive cardiac failure (CCF). Heart failure may occur independent of traditional 
cardiovascular risk factors or in association with one or more of them. For instance, Ukoh103 
et al in their study observed hyperlipidemia in three groups of patients. (1) Hypertensive’s 
with or without heart disease (2) patients with ischemic heart disease and (3) those with 
hypertensive cardiomyopathy. ED may therefore occur in men with heart failure not 
because of the failure itself, but because of the background cardiovascular risk factors 
present. 
The prevalence of heart failure (HF) in the United States, according to the American Heart 
Association, is estimated at 5.3 million.104 ED is present, estimatedly, in 60.8% of heart 
failure patients and prevalence ranging from 81 to 91% has been documented in this 
group.105 In CCF, there is peripheral venous stasis, decreased venous return, reduced stroke 
volume and cardiac output, a must situation for physical in-activity or under-activity. Most 
patients with chronic cardiovascular disease experience decreased libido and frequency of 
sexual activity as well as ED. 
 
 Endothelial dysfunction. 
 Reduced cardiac output. 
 Exercise in tolerance from PH. 
 Associated CVS Risk factors. 
 Drug side effect. 
Table 7. Causes of ED in Heart Failure 
The ED in HF patients is multifactorial in origin. Anxiety or depression may lead to 
performance fears and therefore psychogenic ED. The reduced pulmonary and cardiac 
reserve in CCF patients makes exercise intolerable, bearing in mind that sexual activity 
involve mild to moderate exercise and that most of erectile function is CVS event. Treatment 
of heart failure may lead to ED as a side effect of the drugs used. Diuretics, particular 
thiazides,106are associated with ED through unknown mechanism which may not be 
unconnected with the accompanying electrolyte imbalance. Beta blockers, Digoxin and 
aldosterone are also documented as causing ED. Heart failure is accompanied by endothelial 
dysfunction which as an independent factor, may cause ED in these men.107  
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8. Treatment of ED complicating CVS risk factors and disease 
Following the evaluation of these men (this is beyond the scope of this chapter), there is 
need for treatment in order to improve their quality of life. Gerald et al108 evaluated the 
sexual attitudes and beliefs of middle aged and older adults in non-European ‘Westernized’ 
countries in their work. Approximately 85% of men and women felt that satisfactory sexual 
intercourse is essential for the maintenance of a relationship. Most respondents felt that it is 
acceptable for older men to use medication to enable them to continue to enjoy sexual 
activity. By extension, this is necessary if they are to continue to maintain spousal 
relationship which at this age has profound effect on quality of life and longevity. 
ED is multifactorial in terms of etiology, the implication of which is that treatment should be 
holistic. It is based on this premise that David et al109 proposed a multifaceted approach 
with the argument that no single agent has proven to be highly efficacious. He supported 
this with the work of Goldstein et al110 in which though, 84% of men had improved function 
following treatment with sildenafil, they achieved a fully rigid erection only four times per 
month. This is limiting for a couple and may therefore not be enough to maintain a 
satisfactory relationship. 
9. Life style modification 
9.1 Smoking and alcohol 
According to Feldman et al, 6 smoking doubles the risk of developing ED. Cigarette smoking 
increases the risk of death from CAD and according to Derling et al,111 also the incidence of 
ED. Traditionally, alcohol has been associated with the capacity to lower serum cholesterol 
and therefore improve erectile function. Alcohol has a central sedating effect which may be 
over powering. It is also associated with lowered NO production.112 Men who smoke and 
drink alcohol should be advised to cease smoking and alcohol consumption. The later may 
be restricted to a single daily drink, preferably, red wine which has been documented to 
improve NO production. 
9.2 Regular exercise 
Regular exercise is beneficial to all body tissues and organs particularly in healthy individuals. 
During exercise, the cardiac output, the chronotropic and inotropic activity of the heart 
increase and the circulation therefore becomes more rapid. The blood supply to different 
organs and tissues, particularly the heart and muscles, increase with remarkable improvement 
in tissue perfusion. A sedentary life style is three times as likely to lead to ED where as 
moderate physical activity reduces the risk of ED by two-thirds.113 The sheer stress of increase 
blood flow stimulates the production of NO, an effect which lasts for up to 2-7days with a 
magnitude in the order of fourfold.114 During penile erection, the increase in flow is more than 
this, implying a more increased production of NO. On this premise, some studies have shown 
improved erectile function in men with regular and frequent sexual activity. 
Regular exercise also may help control weight gain, obesity, dyslipidimia and the metabolic 
syndrome. Reduction in weight in the already obese men may lead to regularization of 
testosterone concentration and correct the loss of libido often associated with ED in the 
obese. Men with ED should therefore be advised on regular physical exercise and sexual 
activity.  
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9.3 Modification of diet 
Diet has a profound effect on the general well being and it is part of general healthy living 
that men should be mindful of what they eat. Diet modification can help control weight 
gain, glucose level in diabetes and cholesterol level in dyslipidemic men. When combined 
with regular exercise, the effect may be synergistic with remarkable weight loss and it has 
been documented that about one-third of obese men with ED are able to improve sexual 
function through life style changes.115 Dietary modification should involve the services of a 
trained dietician who should set a target from the beginning, bearing in mind existing co-
morbidities and the age of the patients. 
9.4 Principles of medical treatment 
The medical treatment for erectile dysfunction complicating CVS risk factors and disease 
should necessarily include treating for the underlying risk factors107. These include the 
control of hypertension, diabetes mellitus, dyslipidemia, heart failure and coronary artery 
disease. Although this therapeutic approach, according to Tikkanen et al116, appears 
justified, relatively few intervention studies have investigated the effect of risk factor 
reduction on established ED. However, in the work by Saltzman et al117, artovastatin 
treatment of men with hyperlipidemia as the only risk factor, for instance, led to an 
improvement in erectile function. The medical treatment of these risk factors is beyond this 
chapter but a few guiding principles need to be explained. 
 
Route of Administration  Drugs Used 
1.  Oral 
a.  Phosphodiesterase 5 inhibitors 
1. Sildenafil 
2. Vardanefil 
3. Tadalafil 
b. Peripheral alpha 1 blockers 
1. Phentolamine Mesylate 
c. Central Alpha2 antagonist 
1. Yohimbine 
d. Dopamine agonists 
1. Apomorpine 
2. Intra-Urethral 
a. Direct smooth muscle relaxant 
1. Aprostodil (PGEI) 
3. Intra-cavernosal  
(injectable) 
a. Phosphodiesterase Inhibitor 
1. Papaverine 
b. Peripheral alpha 1 blocker 
1. Phentolamine 
c. Direct smooth muscle relaxant 
1. Aprostodil (PGEI) 
2. Vaso-active intestinal peptide (VIP). 
Table 8. Summary of Drugs used in Pharmacotherapy for ED 
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There are conflicting reports on the effects of the drugs used for specific therapy of these risk 
factors and disease on ED. Statins have been reported to improve erectile function due to 
their positive effect on endothelial function.118 There are however observational reports 
associating statin use with ED.119 Diuretics, calcium channel blockers and beta blockers used 
for the treatment of hypertension and digoxin used for heart-failure have all been reportedly 
linked with ED. The preliminary report of the telmisartan alone, and in combination with 
ramipril global end point trial/telmisartan randomized assessment study in ACE-intolerant 
subjects with cardiovascular Disease (CONTARGET/TRANCEND) study76 shows that 
calcium channel blockers tend to have a significant adverse effect on erectile function while 
treatment with beta blockers, diuretics, ACE inhibitors, ATI antagonist and alpha antagonist 
do not. Treatment with ACE inhibitors, ATI antagonist or a combination of both is 
suggested to improve erectile function in cardiovascular high risk patients. Based on this 
premise, the treating physician is advised to document the base-line erectile function at the 
commencement of treatment as subsequent development of ED is often quoted as 
responsible for non compliance by the affected men who may wish to maintain their 
potency. In the course of treatment, these men should be questioned directly about erectile 
function, and if this wanes or the patients complain, the drugs should be withdrawn. If 
erectile function returns, the drug/drugs can then be documented as the culprit and 
permanently withdrawn. This emphasizes the need for individualization of the 
management of these men. 
Erectile dysfunction has social implications for the couple and any treatment regimen 
should necessarily take the female partner into consideration114. Some modalities of 
treatment may require the co-operation of the female partner due to their psychosocial and 
medical side effects which may be distressful to the couple. For instance, apormorphine may 
cause nausea and or vomiting sometimes necessitating the use of anti-emetics. Table 8 
shows some of the drugs for the treatment of ED, their mode of administration and some of 
their side effects. Also, the use of phosphodiesterase 5 inhibitors is associated with diverse 
reaction which may threaten life. 
9.5 Treatment of ED in CAD and HF patients; Use of PDE 5 inhibitors 
The development and approval for use of the phosphodiesterase 5 inhibitors has 
revolutionized the treatment of erectile dysfunction, but this is not without short-comings 
especially in men with HF and CAD. The main stay of the treatment of CAD is the use of 
nitrates which dilate the coronary arterial bed. The active factor in the nitrates is the nitric-
oxide which it releases and which is also the endothelium dependent vasodilator and 
neurotransmitter mostly responsible for penile erection in man. The phosphodiesterase 5 
inhibitors inhibit the breakdown of nitric oxide, an action which potentiates that of the 
nitrates used for the treatment of CAD. 
Patients with heart disease have a reduced exercise tolerance because of which there is need 
to assess and advise them on fitness to undergo sexual activity. They should be stratified 
into low risk, intermediate risk and high risk based on the presence and number of risk 
factors, angina, previous MI and their New York Heart Association classification status121. 
The amount of energy required for sexual activity has been shown to be about 20-40 
metabolic equivalent of the tasks which is equivalent to doing easy house hood work or 
climbing a flight of stairs. This should guide the physician in advising patients with heart 
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failure provided that aortic stenosis and obstructive valvular cardiomyophathy have been 
excluded. 
Opinions are varied as to whether the phosphodiesterase 5 inhibitors should be used in 
patients who have coronary artery disease and concomitant erectile dysfunction. According 
to George et al121, on the basis of the pharmacokinetic profile of sildenafil for instance, the 
co-administration of a nitrate within the first 24 hours is likely to produce a severe, 
potentially, life threatening hypotensive response and it is therefore contradicted. However, 
Parker et al122 insist in their work that though contradicted, there are occasions when a 
patient who has recently taken a phosphodiesterase 5 inhibitor might need intravenous 
nitroglycerin treatment with the proviso that such patients should be closely monitored and 
should have stable CAD. In the work by Webb et al,123 when sublingual nitroglycerin was 
administered, there was a fourfold decrease in systolic blood pressure In patients with 
sildenafil treatment. Their conclusion was that sildenafil potentiated the hypotensive effect of 
nitrates and their concomitant use was absolutely contra indicated. According to Velasquez et 
al124 adverse cardiac event associated to sildenafil use, for instance, include MI, angina, 
ventricular tachycardia and death. Therefore, the use of phosphodiesterase 5 inhibitors and 
nitrates in men with ED and concomitant CAD should be done with caution, individualized 
and in consultation between the physician and Urologist in order to optimize care. 
10. Surgical treatment 
Surgical treatment of ED has been relegated to the background as the last option with the 
advent of effective medical therapy. The main-stay of surgical treatment includes the use of 
penile implants and penile arterial revascularization procedures.125 Infection is a major 
setback in the use of penile implants particularly in DM.Penile revascularization procedures 
may be complicated by numbness of the glans and penile skin, defeating the aim of the 
surgery. Penile venous surgery is presently considered historical. 
11. Use of vacuum erection devices 
These devices induce erection by increasing corporal perfusion and or impeding venous 
return.126 Their efficacy profile is good but non compliance by patients is high due to 
difficulty with operating them and the associated ejaculatory problems. In truth, vacuum 
erection devices cause a hinged erection and the penis is rather truly not rigid. 
12. Conclusion  
Endothelial dysfunction and atherosclerosis are the pathways through which cardiovascular 
risk factors predispose to coronary artery disease, stroke and erectile dysfunction, the ED 
occurring earlier because of the small size of the pudendal artery which supplies the 
cavernous bed. As atherosclerosis is a progressive and dynamic disease, larger vessels are 
eventually involved and this often includes the coronary artery with the development of 
CAD. ED is presently regarded as a sentinel event for CAD and patients who present with 
ED with no other risk factors should be evaluated for silent CAD. The drugs used for the 
treatment of CVS risk factors may have ED as side effect and patients should therefore be 
questioned directly for the occurrence of ED. The concomitant use of nitrates and 
phosphodiesterase 5 inhibitors calls for caution.  
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